The enzyme dipeptidyl peptidase-4 (DPP-4) prevents the inactivation of glucagon-like peptide-1 (GLP-1). Since GLP-1-based therapy is a promising novel treatment of type 2 diabetes, the strategy to ...

Scientists found that patients taking GLP-1RAs reported fewer symptoms of depression than those on the common diabetes drug dipeptidyl peptidase-4 inhibitors (DPP4is), also known collectively as ...

Type 2 diabetes mellitus (T2DM) is a prevalent yet complex metabolic disorder that has shown a rising incidence over the past few decades. Recent research has identified flavonoids as compounds ...

Among patients with diabetes receiving PCI, novel antidiabetic agents may reduce risk for acute kidney injury.

Emerging evidence shows glucose-lowering medications may have the potential to improve chronic obstructive pulmonary disease ...

or dipeptidyl peptidase-4 inhibitors (DPP4is). The data showed that risk for depression was low overall, with no difference in incidence when comparing GLP-1RAs to SGLT2is and a modestly reduced ...

M ONDAY, March 3, 2025 (HealthDay News) -- Glucagon-like peptide-1 (GLP-1) receptor agonists are not associated with an increased risk for suicidality compared with dipeptidyl peptidase-4 (DPP-4 ...

Azoulay and colleagues found no increase in suicidality risk when comparing GLP-1 receptor agonists with two other commonly prescribed drug classes (dipeptidyl peptidase-IV [DPP-IV] inhibitors and ...

Please provide your email address to receive an email when new articles are posted on . GLP-1s reduced depression risk vs. DPP-4 inhibitors but not SGLT2 inhibitors. However, both GLP-1s and SGLT2 ...

Ali, H. , Ghaysaa, H. , Jaafar, W. and Malek, M. (2025) Ischemic Stroke Following Coronary Angiography: A Case Report. Case ...

The 12-month price targets, analyzed by analysts, offer insights with an average target of $98.62, a high estimate of $110.00, and a low estimate of $90.00. Witnessing a positive shift, the current ...